HC Wainwright Weighs in on Pyxis Oncology Q1 Earnings

Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Pyxis Oncology in a report released on Monday, May 19th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings per share of ($0.46) for the quarter. HC Wainwright currently has a "Buy" rating and a $5.00 price target on the stock. The consensus estimate for Pyxis Oncology's current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Pyxis Oncology's Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.38) EPS and FY2029 earnings at $0.18 EPS.

Separately, Royal Bank of Canada reiterated an "outperform" rating and set a $8.00 target price on shares of Pyxis Oncology in a research report on Wednesday, March 19th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $9.00.

Pyxis Oncology Price Performance

Shares of Pyxis Oncology stock opened at $1.23 on Tuesday. Pyxis Oncology has a 1 year low of $0.83 and a 1 year high of $5.39. The firm has a market cap of $76.20 million, a PE ratio of -1.19 and a beta of 1.15. The company has a 50 day simple moving average of $1.05 and a two-hundred day simple moving average of $1.60.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.06).

Institutional Investors Weigh In On Pyxis Oncology

Hedge funds have recently bought and sold shares of the stock. Barclays PLC lifted its holdings in shares of Pyxis Oncology by 275.0% in the 3rd quarter. Barclays PLC now owns 64,089 shares of the company's stock worth $235,000 after acquiring an additional 46,997 shares during the last quarter. American Century Companies Inc. grew its stake in shares of Pyxis Oncology by 88.1% during the fourth quarter. American Century Companies Inc. now owns 299,937 shares of the company's stock valued at $468,000 after buying an additional 140,498 shares during the last quarter. Caption Management LLC bought a new position in shares of Pyxis Oncology during the fourth quarter valued at about $35,000. Renaissance Technologies LLC grew its stake in shares of Pyxis Oncology by 83.0% in the fourth quarter. Renaissance Technologies LLC now owns 293,354 shares of the company's stock worth $458,000 after purchasing an additional 133,018 shares during the last quarter. Finally, Ridgeback Capital Investments L.P. bought a new stake in shares of Pyxis Oncology in the fourth quarter worth about $560,000. 39.09% of the stock is currently owned by institutional investors.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.